Definately on the buyout listThough i'll take all cap appreciation. Been building a new base and on any news will reach the $12.50 - $13.50 range per many analyst targets. Even the big original believers like Smedley and Donneville that were picking up under $10 will want their pound of flesh return. On top of the results, good pipeline in the works and they are on the acquisition front. Everything is pricey out there -YES - but for a reason. Demand is growing like crazy with the aging population and returns are growing astronomically. What a great sector to be in. You decide if RX is a good stock that will benefit from the growth in the sector. Sure looks good this vantage point!